



国内版 国际版

Rifaximin improves survival in cirrhotic patients with refractory



ALL

IMAGES

VIDEOS

开启取词

27,000 Results

Any time ▾

Randomised clinical trial: rifaximin improves health ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04808.x>

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study A. Sanyal Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

Cited by: 115 Author: A. Sanyal, Z. M. Younossi, N. M. Bass, ...

Publish Year: 2011

TIPS improves liver transplantation-free survival in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949280>

Mar 14, 2014 · We pooled the overall survival of this study in a sensitivity analysis to demonstrate a conservative result, which also showed an improvement of LTF survival in the TIPS group. All of these results suggest that TIPS could improve LTF survival in selected cirrhotic patients with refractory ascites.

Cited by: 69 Author: Ming Bai, Xing-Shun Qi, Zhi-Ping Yang, M...

Publish Year: 2014

Evaluation and management of patients with refractory ascites

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653293>

Jan 07, 2009 · Cirrhotic patients who develop ascites have a probability of survival of 85% at 1 year and 56% at 5 years without liver transplantation. In patients who become resistant to diuretic therapy, the prognosis decreases to 50% survival at 2 years. Patients with refractory ascites have lower sodium excretion compared to sensitive patients.

Cited by: 60 Author: Bahaa Eldeen Senousy, Peter V Draganov

Publish Year: 2009

[PDF] Minimizing Complications in Cirrhosis

<https://louisville.edu/.../management-of-complications-in-cirrhosis-2016>

• In Cirrhosis with renal dysfunction or refractory ascites, long term: – Pentoxifylline improves diuresis and natriuresis; increases, MAP, SVR and serum sodium; and decreases risk of HRS.

Rifaximin and midodrine improve clinical outcome in ...

<https://reference.medscape.com/medline/abstract/27622998> ▾

Chat with Bing



Is your goal want to chat with me?

Say something ...

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 51793

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study

Abstract

BACKGROUND

Rifaximin has been shown to reduce the incidence of hepatic encephalopathy and other complications in patients with cirrhosis. However, few studies have investigated the effect of rifaximin in cirrhotic patients with refractory ascites.

Match Overview

1	Crossref 20 words Nina Kimer, Julie S Pedersen, Juliette Tavenier, Jeffrey E Christensen et al. "Rifaximin has minor effects on bacterial c	<1%
2	Internet 19 words crawled on 02-Jul-2018 www.karger.com	<1%
3	Crossref 17 words Jasmohan S. Bajaj, Douglas M. Heuman, Arun J. Sanyal, Phillip B. Hylemon et al. "Modulation of the Metabiome by F...	<1%
4	Internet 12 words crawled on 23-Jul-2019 www.tandfonline.com	<1%



国内版 国际版

Rifaximin improves survival in cirrhotic patients with refractory



Chat with Bing

Sign in



All

Images

Videos

关闭取词

Add Bing Firefox extension >

26,900 Results

Any time ▾

Randomised clinical trial: rifaximin improves health ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04808.x>

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study A. Sanyal Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

Cited by: 113

Author: A. Sanyal, Z. M. Younossi, N. M. Bass, ...

Publish Year: 2011

TIPS improves liver transplantation-free survival in ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3949280>

Mar 14, 2014 · We pooled the overall survival of this study in a sensitivity analysis to demonstrate a conservative result, which also showed an improvement of LTF survival in the TIPS group. All of these results suggest that TIPS could improve LTF survival in selected cirrhotic patients with refractory ascites.

Cited by: 69

Author: Ming Bai, Xing-Shun Qi, Zhi-Ping Yang, M...

Publish Year: 2014

Rifaximin treatment is associated with reduced risk of ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/apt.14275>

Until now, only several small short-term studies have reported the effect of rifaximin treatment in patients with cirrhosis. One study showed that the 5-year cumulative probability of survival was higher in patients receiving rifaximin (n = 23) than in patients not receiving rifaximin (n = 46). 25 These results are consistent with our study ...

Cited by: 23

Author: S. H. Kang, S. H. Kang, Y. B. Lee, J. H. ...

Publish Year: 2017

Evaluation and management of patients with refractory ascites

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653293>

Jan 07, 2009 · Cirrhotic patients who develop ascites have a probability of survival of 85% at 1 year and 56% at 5 years without liver transplantation. In patients who become resistant to diuretic therapy, the prognosis decreases to 50% survival at 2 years. Patients with refractory ascites have lower sodium excretion compared to sensitive patients.

Cited by: 62

Author: Bahaa Eldeen Senousy, Peter V Draganov

Publish Year: 2009



ALL

IMAGES

VIDEOS

关闭取词

26,900 Results

Any time ▾

Randomised clinical trial: rifaximin improves health ...

<https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2036.2011.04808.x>

Randomised clinical trial: rifaximin improves health-related quality of life in cirrhotic patients with hepatic encephalopathy – a double-blind placebo-controlled study A. Sanyal Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.

Cited by: 113

Author: A. Sanyal, Z. M. Younossi, N. M. Bass, ...

Publish Year: 2011

Evaluation and management of patients with refractory ascites

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2653293>

Jan 07, 2009 · Cirrhotic patients who develop ascites have a probability of survival of 85% at 1 year and 56% at 5 years without liver transplantation. In patients who become resistant to diuretic therapy, the prognosis decreases to 50% survival at 2 years. Patients with refractory ascites have lower sodium excretion compared to sensitive patients.

Cited by: 62

Author: Bahaa Eldeen Senousy, Peter V Draganov

Publish Year: 2009

Improving Survival in Decompensated Cirrhosis

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3395145>

Jul 02, 2012 · Patients with refractory ascites have median survival of 6 months. The mainstay of treatment is repeated LVP and in selected cases, TIPS. The mainstay of treatment is repeated LVP and in selected cases, TIPS.

Cited by: 11

Author: Amar Nath Mukerji, Vishal Patel, Ashokk...

Publish Year: 2012

Management of refractory ascites in patients with cirrhosis

<https://www.bsg.org.uk/.../refractory-ascites-in-cirrhosis-patients.html> ▾

Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int 2019;39:98–105. Ibach P, Höner Zu Siederdisen C, Wellhöner F et al. Automated low-flow ascites pump in a real-world setting: complications and outcomes.

Minimizing Complications in Cirrhosis